Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I

Human Gene Therapy

Volumn 8, Issue 5, 1997, Pages 513-521

  Overturf, Ken ^a   Al Dhalimy, Muhsen ^a   Ou, Ching Nan ^b   Finegold, Milton ^b   Tanguay, Robert ^c   Lieber, Andre ^d   Kay, Mark ^d   Grompe, Markus ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARYLACETOACETASE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME DEFICIENCY; EXPRESSION VECTOR; GENE THERAPY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION TEST; MOUSE; MOUSE MUTANT; NONHUMAN; TYROSINEMIA; VIRUS INFECTION;

EID: 0030917824     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.5-513     Document Type: Article

References (38)

1. BARR, D., TUBB, J., FERGUSON, D., SCARIA, A., LIEBER, A., WILSON, C., PERKINS, J., and KAY, M.A. (1995). Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2, 151-155.
2. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
3. CHOWDHURY, J.R., GROSSMAN, M., GUPTA, S., CHOWDHURY, N.R., BAKER, J.R., JR., and WILSON, J.M. (1991). Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 254, 1802-1805.
4. FISHER, K.J., CHOI, H., BURDA, J., CHEN, S.J., and WILSON, J.M. (1996). Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217, 11-22.
5. GRAHAM, F.L., and PREVEC, L. (1991). Manipulation of adenovirus vectors. In Methods in Molecular Biology - Gene Transfer and Expression Techniques. E.J. Murray and J.M. Walker, eds. (Humana Press Inc., Clifton, NJ) pp. 109-128.
6. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
7. GRE, G.O., COFFMAN, W.D., and KUBICEK, M.T. (1952). Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. Cancer Res. 12, 264-265.
8. GRENIER, A., and LESCAULT, A. (1985). Succinylacetone. In Methods of Enzymatic Analysis. H. Bergmeyer, eds. (VCH Verlagsgesellschaft, Weinheim, Germany) p. 79.
9. GROMPE, M., AL-DHALIMY, M., FINEGOLD, M., OU, C.N., BURLINGAME, T., KENNAWAY, N.G., and SORIANO, P. (1993). Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes & Dev. 7, 2298-2307.
10. GROMPE, M., LINDSTEDT, S., AL-DHALIMY, M., KENNAWAY, N.G., PAPACONSTANTINOU, J., TORRES-RAMOS, C.A., OU, C.N., and FINEGOLD, M. (1995). Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nature Genet. 10, 453-460.
11. GROSSMAN, M., and WILSON, J.M. (1993). Retroviruses: Delivery vehicle to the liver. Curr. Opin. Genet. Dev. 3, 110-114.
12. GROSSMAN, M., RAPER, S.E., KOZARSKY, K., STEIN, E.A., ENGELHARDT, J.F., MULLER, D., LUPIEN, P.J., and WILSON, J.M. (1994). Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia. Nature Genet. 6, 335-341.
13. HORWICH, A.L. (1991). Inherited hepatic enzyme defects as candidates for liver-directed gene therapy. Curr. Top. Microbiol. Immunol. 168, 185-200.
14. KASS-EISLER, A., FALCK-PEDERSEN, E., ALVIRA, M., RIVERA, J., BUTTRICK, P.M., WITTENBERG, B.A., CIPRIANI, L., and LEINWAND, L.A. (1993). Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc. Natl. Acad. Sci. USA 90, 11498-11502.
15. KAY, M.A., LI, Q., LIU, T.J., LELAND, F., TOMAN, C., FINEGOLD, M., and WOO, S.L. (1992). Hepatic gene therapy: persistent expression of human alpha 1-antitrypsin in mice after direct gene delivery in vivo. Hum. Gene Ther. 3, 641-647.
16. KAY, M.A., LANDEN, C.N., ROTHENBERG, S.R., TAYLOR, L.A., LELAND, F., WIEHLE, S., FANG, B., BELLINGER, D., FINEGOLD, M., THOMPSON, A.R., READ, M., BRINKHOUSE, K.M., and WOO, S.L.C. (1994). In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc. Natl. Acad. Sci. USA 91, 2353-2357.
17. KAY, M.A., HOLTERMAN, A.X., MEUSE, L., GOWN, A., OCHS, H.D., LINSLEY, P.S., and WILSON, C.B. (1995). Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nature Genet. 11, 191-197.
18. KELSEY, G., RUPPERT, S., BEERMANN, F., GRUND, C., TANGUAY, R.M., and SCHÜTZ, G. (1993). Rescue of mice homozygous for lethal albino deletions: Implications for an animal model for the human liver disease tyrosinemia type I. Genes & Dev. 7, 2285-2297.
19. KNOX, W.E., and EDWARDS, S.W. (1995). Enzymes involved in conversion of tyrosine to acetoacetate. Methods Enzymol. 2, 287-300.
20. KOCHANEK, S., CLEMENS, P.R., MITANI, K., CHEN, H.H., CHAN, S., and CASKEY, C.T. (1996). A new adenoviral vector: Replacement of all viral coding sequences with 28 Kb of DNA independently expressing both full length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. USA 83, 5731-5736.
21. KOZARSKY, K., GROSSMAN, M., and WILSON, J.M. (1993). Adenovirus-mediated correction of the genetic defect in hepatocytes from patients with familial hypercholesterolemia. Somat. Cell Mol. Genet. 19, 449-458.
22. KVITTINGEN, E.A., ROOTWELT, H., BRANDTZAEG, P., BERGAN, A., and BERGER, R. (1993). Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. J. Clin. Invest. 91, 1816-1821.
23. KVITTINGEN, E.A., ROOTWELT, H., BERGER, R., and BRANDTZAEG, P. (1994). Self-induced correction of the genetic defect in tyrosinemia type I. J. Clin. Invest. 94, 1657-1661.
24. LABELLE, Y., PUYMIRAT, J., and TANGUAY, R.M. (1993). Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1. Biochim. Biophys. Acta 1180, 250-256.
25. LI, Q., KAY, M.A., FINEGOLD, M., STRATFORD-PERRICAUDET, L.D., and WOO, S.L. (1993). Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 4, 403-409.
26. LINDSTEDT, S., HOLME, E., LOCK, E.A., HJALMARSON, O., and STRANDVIK, B. (1992). Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340, 813-817.
27. MITCHELL, G.A., LAMBERT, M., and TANGUAY, R.M. (1994). Hypertyrosinemia. In The Metabolic Basis of Inherited Disease. C.R. Scriver, A.L. Beaudet, W. Sly, and D. Valle, eds. (MacGraw-Hill, New York) pp. 1077-1106.
28. MORSY, M.A., ALFORD, E.L., BETT, A., GRAHAM, F.L., and CASKEY, C.T. (1993). Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes. J. Clin. Invest. 92, 1580-1586.
29. MURCIA, F.J., VAZQUEZ, J., GAMEZ, M., LOPEZ-SANTAMARIA, M., DE-LA-VEGA, A., DIAZ, M.C., JARA, P., and TOVAR, J. (1995). Liver transplantation in type I tyrosinemia. Transplant Proc. 27, 2301-2302.
30. OVERTURF, K., AL-DHALIMY, M., TANGUAY, R., BRANTLY, M., OU, C.N., FINEGOLD, M., and GROMPE, M. (1996). Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinemia type I. Nature Genet. 12, 266-273.
31. PARADIS, K., WEBER, A., SEIDMAN, E.G., LAROCHELLE, J., GAREL, L., LENAERTS, C., and ROY, C.C. (1990). Liver transplantation for hereditary tyrosinemia: The Quebec experience. Am. J. Hum. Genet. 47, 338-342.
32. PHANEUF, D., LABELLE, Y., BÉRUBÉ, D., ARDEN, K., CAVENEE, W., GAGNÉ, R., and TANGUAY, R.M. (1991). Cloning and expression of the cDNA encoding human fumarylacetoacetae hydrolase, the enzyme deficient in hereditary tyrosinemia: Assignment of the gene to chromosome 15. Am. J. Hum. Genet. 48, 525-535.
33. SAMBROOK, J., FRITSCH, E.F., and MANIATIS, T. (1989). Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
34. SCRIVER, C.R., BEAUDET, A.L., SLY, W., and VALLE, D. (Ed.). (1994). The Metabolic Basis of Inherited Disease, 7th ed. (MacGraw-Hill, New York).
35. SPENCER, P.D., and ROTH, K.S. (1987). Effects of succinylacetone on amino acid uptake in the rat kidney. Biochem. Med. Metab. Biol. 37, 101-109.
36. STRATFORD-PERRICAUDET, L.D., LEVRERO, M., CHASSE, J.F., PERRICAUDET, M., and BRIAND, P. (1990). Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum. Gene Ther. 1, 241-256.
37. WYSS, P.A., BOYNTON, S.B., CHU, J., SPENCER, R.F., and ROTH, K.S. (1992). Physiological basis for an animal model of the renal Fanconi syndrome: Use of succinylacetone in the rat. Clin. Sci. 83, 81-87.
38. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GONCZOL, E., and WILSON, J.M. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91, 4407-4411.